2seventy bio, Inc. stock is down -22.4% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 0% of analysts rate it a buy.
2seventy bio, Inc. focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.